The role of organ- and function-preserving radiotherapy in the treatment of adenoid cystic carcinoma of the larynx.


Journal

Head & neck
ISSN: 1097-0347
Titre abrégé: Head Neck
Pays: United States
ID NLM: 8902541

Informations de publication

Date de publication:
07 2019
Historique:
received: 19 09 2018
revised: 02 01 2019
accepted: 10 01 2019
pubmed: 7 2 2019
medline: 18 11 2020
entrez: 7 2 2019
Statut: ppublish

Résumé

To evaluate clinical outcome and functional larynx preservation after radiotherapy (RT) for adenoid cystic carcinoma (ACC) of the larynx. Eleven patients with primary ACC of the larynx, who received RT definitely (n = 5/11) or postoperatively (n = 6/11), were analyzed regarding survival and treatment-related toxicity with the focus on functional larynx preservation. Median follow-up was 45 months. RT offered an excellent 5-year local control (LC) rate of 100%. Eight of 11 patients were treated with a laryngeal preservation approach (LPA). At last follow-up, only one of these eight patients developed a local recurrence requiring a total laryngectomy 11 years after treatment. Severe toxicity was uncommon, with only one patient with LPA, requiring a temporary tracheostomy during therapy. RT is an effective treatment method for laryngeal ACC with excellent LC rates, preservation of the laryngeal function and voice formation, representing a valuable therapy alternative to total laryngectomy.

Sections du résumé

BACKGROUND
To evaluate clinical outcome and functional larynx preservation after radiotherapy (RT) for adenoid cystic carcinoma (ACC) of the larynx.
METHODS
Eleven patients with primary ACC of the larynx, who received RT definitely (n = 5/11) or postoperatively (n = 6/11), were analyzed regarding survival and treatment-related toxicity with the focus on functional larynx preservation.
RESULTS
Median follow-up was 45 months. RT offered an excellent 5-year local control (LC) rate of 100%. Eight of 11 patients were treated with a laryngeal preservation approach (LPA). At last follow-up, only one of these eight patients developed a local recurrence requiring a total laryngectomy 11 years after treatment. Severe toxicity was uncommon, with only one patient with LPA, requiring a temporary tracheostomy during therapy.
CONCLUSIONS
RT is an effective treatment method for laryngeal ACC with excellent LC rates, preservation of the laryngeal function and voice formation, representing a valuable therapy alternative to total laryngectomy.

Identifiants

pubmed: 30723979
doi: 10.1002/hed.25678
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2208-2214

Subventions

Organisme : University Hospital Heidelberg
Pays : International

Informations de copyright

© 2019 Wiley Periodicals, Inc.

Auteurs

Sati Akbaba (S)

Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany.
Department of Radiation Oncology, Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.
Department of Radiation Oncology, Heidelberg Ion-Beam Therapy Center (HIT), Heidelberg, Germany.

Kristin Lang (K)

Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany.
Department of Radiation Oncology, Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.
Department of Radiation Oncology, Heidelberg Ion-Beam Therapy Center (HIT), Heidelberg, Germany.

Olcay Cem Bulut (OC)

Department of Otolaryngology, Head and Neck Surgery, University Hospital Heidelberg, Heidelberg, Germany.

Thomas Held (T)

Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany.
Department of Radiation Oncology, Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.
Department of Radiation Oncology, Heidelberg Ion-Beam Therapy Center (HIT), Heidelberg, Germany.

Stefan Rieken (S)

Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany.
Department of Radiation Oncology, Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.
Department of Radiation Oncology, Heidelberg Ion-Beam Therapy Center (HIT), Heidelberg, Germany.

Peter Plinkert (P)

Department of Otolaryngology, Head and Neck Surgery, University Hospital Heidelberg, Heidelberg, Germany.

Alexandra Jensen (A)

Department of Radiation Oncology, University Hospital Giessen, Gießen, Germany.

Klaus Herfarth (K)

Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany.
Department of Radiation Oncology, Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.
Department of Radiation Oncology, Heidelberg Ion-Beam Therapy Center (HIT), Heidelberg, Germany.

Juergen Debus (J)

Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany.
Department of Radiation Oncology, Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.
Department of Radiation Oncology, Heidelberg Ion-Beam Therapy Center (HIT), Heidelberg, Germany.

Sebastian Adeberg (S)

Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany.
Department of Radiation Oncology, Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.
Department of Radiation Oncology, Heidelberg Ion-Beam Therapy Center (HIT), Heidelberg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH